Women with a higher risk of developing breast cancer are set to be offered a pill that cuts their risk of developing the disease in half. NHS England and UK medication watchdogs announced the pill ...
Please provide your email address to receive an email when new articles are posted on . Adding the ER antagonist fulvestrant to anastrozole provided no benefit to women with hormone-receptor-positive ...
August 7, 2006 — Anastrazole should now be the preferred initial adjuvant treatment for postmenopausal women with hormone-sensitive early-stage breast cancer, instead of the current standard, ...
Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: an active regimen with limiting neurotoxicity. The median follow-up duration was approximately 6 months. The estimated ...
High-Dose Versus Standard Chemotherapy in Metastatic Breast Cancer: Comparison of Cancer and Leukemia Group B Trials With Data From the Autologous Blood and Marrow Transplant Registry PURPOSE: To ...
A drug previously used to treat breast cancer is now being offered to high risk women as a preventative measure. NHS chief executive Amanda Pritchard said: “It’s fantastic that this vital ...
September 8, 2008 — The foveas of women using anastrozole to prevent breast cancer recurrence appear to be subjected to more tractional force than the foveas of women not using any hormonal medication ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Carpal tunnel ...
Compared with anastrozole alone, the combination of fulvestrant and anastrozole significantly improved time without disease progression and extended the median overall survival of women with endocrine ...
Please provide your email address to receive an email when new articles are posted on . SAN ANTONIO — Postmenopausal women with ductal carcinoma in situ experienced comparable rates of recurrence but ...
The aromatase inhibitor anastrozole inhibits estrogen synthesis. Fulvestrant binds and accelerates degradation of estrogen receptors. We hypothesized that these two agents in combination might be more ...
The Queen Mary University of London professor leading an international breast cancer study says anastrozole - rather than tamoxifen - should be the preventive drug-of-choice for post-menopausal women ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results